NCT05398562View on ClinicalTrials.gov

Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 13, 2020

Primary Completion Date

June 17, 2020

Study Completion Date

June 26, 2020

Conditions
TuberculosisSkin Tests
Interventions
DIAGNOSTIC_TEST

Mycobacterial recombinant allergens 0.1 μg

solution for intradermal injection, 0.1 µg / 0.1 mL

DIAGNOSTIC_TEST

Mycobacterial recombinant allergens 0.2 μg

solution for intradermal injection, 0.2 µg / 0.1 mL

DIAGNOSTIC_TEST

Placebo

solution for intradermal injection

Trial Locations (1)

Unknown

"Limited Liability Company Scientific Research Center Eco-Safety", Saint Petersburg

All Listed Sponsors
lead

St. Petersburg Research Institute of Vaccines and Sera

OTHER_GOV

NCT05398562 - Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers | Biotech Hunter | Biotech Hunter